Notice of Proposed Sale · 144
Scholar Rock Holding Corporation
SRRKNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Scholar Rock Holding Corp.
- Issuer CIK
- 0001727196
- SEC file number
- 001-38501
- Phone
- 857-259-3860
- Person for whose account securities are to be sold
- Katie Peng
- Relationships to issuer
- Director
- Street
- 301 Binney Street, 3rd Floor
- City
- Cambridge
- State / country code
- MA
- Postal code
- 02142
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 1,006 | 48,610 | 121,785,282 | 10/01/2026 | Nasdaq | J.P. Morgan Securities LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- J.P. Morgan Securities LLC
- Street
- 270 Park Avenue
- Street (continued)
- 10th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10017
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/15/2026 | RSU | Issuer | 261 | N | 08/15/2026 | NA |
| Common | 09/15/2026 | RSU | Issuer | 745 | N | 09/15/2026 | NA |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 10/01/2026
- Signed
- /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Katie Peng.
- Plan adoption dates
- 03/20/2026
Company context
Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Scholar Rock intends to commercialize ISEMBYLD (apitegromab-mstn) globally, beginning in the U.S. for individuals living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.